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Abstract: A series of reports in the past decade have ascribed pro-angiogenic activity to several thyroid hormone 
analogues, including L-thyroxine (T4), 3,5,3-triiodo-L-thyronine (T3) and diiodothyropropionic acid (DITPA). Model 
systems of angiogenesis have demonstrated that thyroid hormone-induced neovascularization is initiated at a cell surface 
receptor for the hormone on an integrin. The hormone signal is transduced within the cell by extracellular regulated kinase 
1/2 (ERK1/2) into secretion of basic fibroblast growth factor (bFGF) and other vascular growth factors and consequent 
angiogenesis. Intact animal studies have shown that endogenous thyroid hormone supports blood vessel density in heart 
and brain and that thyroid hormone administration can induce angiogenesis in ischemic limbs.  
INTRODUCTION 
  In studies of thyroid hormone-induced myocardial 
hypertrophy a decade ago, Tomanek and co-workers showed 
that administration of L-thyroxine (T4) to rats caused left 
ventricular capillary growth [1]. This was accompanied by 
accumulation of basic fibroblast growth factor (bFGF) 
mRNA and bFGF protein. Because these changes occurred 
within several days of animal exposure to T4, when the 
hypertrophic response was small, the authors concluded in 
this study and in a follow-up report [1, 2] that the vascular 
and myocyte actions of thyroid hormone in this model 
represented separate effects of T4. The same laboratory 
subsequently found that an inotropic iodothyronine 
analogue, diiodothyropropionic acid (DITPA), increased 
abundance of vascular endothelial growth factor (VEGF) 
protein and angiopoietin-1 (Ang-1) in rat coronary arterioles, 
as well as bFGF [3]. There was no increase in ventricular 
mass in the treated animals. The molecular basis of the 
thyroid hormone effect on bFGF and other growth factor 
gene expression was not investigated. An effect of the 
thyroid hormone analogue on Ang-1 was puzzling, since this 
factor stabilizes quiescent endothelium, whereas Ang-2 is a 
de-stabilizing agent that prepares previously quiescent 
endothelium for the action of growth factors such as VEGF 
[4]. The structures of pro-angiogenic thyroid hormone 
analogues are shown in Fig. (1). 
  The cardiomyopathic hamster was recently shown by 
Kuzman et al. to respond to chronic DITPA administration 
with an increase in myocardial blood flow [5] consistent 
with increased angiogenesis. Subsequently, this group 
reported that hypothyroidism decreased blood vessel density 
in rat brain [6] and heart [7] and that administration of 
DITPA or T4 to thyroidectomized animals prevented blood 
vessel loss. Several clinical studies have asserted that thyroid 
hormone as L-thyroxine may be effective in heart failure [8, 
9] but the state of the coronary circulation before and during 
treatment is not known. Clinical trials of DITPA in the   
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management of heart failure, conducted by the Department 
of Veterans Affairs and Titan Pharmaceuticals, Inc., have 
been terminated (ClinicalTrials.gov), but a hypolipidemic 
trial continues.  
  The existence of a discrete effect of thyroid hormone 
analogues on angiogenesis has been documented in the chick 
chorioallantoic membrane model (CAM) [10, 11] and in the 
human dermal microvascular endothelial cell (HDMEC) 
microtubular model [11, 12]. The molecular basis of this 
effect has been defined and shown to be initiated at a cell 
surface receptor for thyroid hormone on endothelial cells that 
we have recently described [11, 13, 14]. Thus, a nuclear 
thyroid hormone receptor (TR) isoform [15] is not primarily 
involved in the pro-angiogenic action of the hormone.  
  The concept of thyroid hormone as a pro-angiogenic 
agent is relevant to the clinical use of hormone analogues as 
inotropic [16, 17] or cholesterol-lowering agents [18, 19]. 
Pro-angiogenic agents may also be of interest in accelerating 
wound-healing. Thyroid hormone has been reported to 
accelerate wound-healing, but this has been attributed to an 
action of the hormone on keratinocytes [20]. In the setting of 
cancer, in contrast, anti-angiogenesis is desirable and anti-
angiogenic clinical strategies are being extensively explored 
[21, 22].  
THYROID HORMONE ACTION AT ITS CELL 
SURFACE RECEPTOR ON INTEGRIN V3  
  In 2005, Bergh et al. demonstrated the existence of a 
high affinity thyroid hormone receptor on a structural plasma 
membrane protein, integrin v3 [13]. A number of 
extracellular matrix (ECM) proteins are ligands of this 
heterodimeric protein [23] and the binding of each of these is 
a signal that is transduced by the integrin into an intracellular 
response (outside-in signaling). The protein can also 
transduce intracellular signals into extracellular events 
(inside-out signaling). The extracellular domain of this 
integrin includes an Asp-Gly-Asp (RGD) recognition site 
that is an important verification domain for the ligands of the 
protein; that is, each of the integrin ligands contain an RGD 
sequence that is required for the binding of each ECM 
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integrin [23]. There may also be crosstalk between the RGD 
recognition site on v3 and specific vascular growth factor 
receptors that may be clustered with the integrin [24, 25]. 
The initial description of the plasma membrane integrin 
receptor included evidence that the receptor mediated the 
effect of the hormone on angiogenesis [13], which had been 
previously reported [10]. 
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Fig. (1). Structures of thyroid hormone analogues. L-Thyroxine 
(T4), 3, 5, 3’-triiodo-L-thyronine (T3) and DITPA (diiodo-
thyropropionic acid) are pro-angiogenic and initiate angiogenesis at 
the integrin v3 receptor for thyroid hormone. The receptor is 
located at the Arg-gly-Asp (RGD) recognition site on the integrin. 
Tetrac (tetraiodothyroacetic acid) is a deaminated derivative of T4 
and is anti-angiogenic, blocking the binding of agonist thyroid 
hormone analogues at the integrin receptor. Tetrac is also capable 
of inhibiting the angiogenic actions of vascular endothelial growth 
factor (VEGF) and basic fibroblast growth factor (bFGF) in the 
absence of thyroid hormone. Action of the growth factors requires 
crosstalk between the integrin RGD recognition domain and the 
specific receptors for the VEGF and bFGF. 
  The thyroid hormone receptor on integrin v3 is located 
at the RGD recognition site and short RGD peptides interfere 
with the binding of thyroid hormone analogues to the 
integrin. T4 and 3,5,3’-triiodo-L-thyronine (T3) are agonist 
ligands at the hormone receptor site and are physiologically 
the most important thyroid hormone analogues. DITPA and 
GC-1 are iodothyronine analogues that also are agonist 
ligands at the integrin receptor [11, 14]. The thyroid 
hormone signal initiated at integrin v3 is transduced by 
the mitogen-activated protein kinase (MAPK; extracellular 
regulated kinase, ERK1/2) cascade [10, 13]. The kinase 
activities upstream of MAPK for the thyroid hormone signal 
initiated at the cell surface have been identified [26], and 
several complex downstream events occur as a result of the 
activation of ERK1/2 by thyroid hormone. Such events may 
be local, e.g., regulation of the activity of the plasma 
membrane Na/H antiporter [27] that is important to 
myocardial function [28] or an increase in activity of cell 
membrane Na, K-ATPase (sodium pump) activity [29].  
  Other events initiated at the integrin involve several 
cellular compartments and include trafficking of proteins 
within the cell [30, 31] and complex cellular actions, such as 
angiogenesis [10]. Proteins in cytoplasm that translocate to 
the nucleus in response to the binding of thyroid hormone by 
the plasma membrane integrin receptor include activated 
ERK1/2 [26], and other signal transducing proteins [32, 33]. 
By this mechanism that does not primarily involve the 
nuclear receptor for thyroid hormone, the latter can amplify 
the intracellular responses to important systemic 
polypeptides that act at the plasma membrane. Examples of 
such polypeptides are interferon- [32] and epidermal growth 
factor-like ligands [33, 34].  
  The pro-angiogenic effect of thyroid hormone that is 
initiated at the integrin is induced by several thyroid 
hormone analogues, as noted above. The analogues are not 
interchangeable as angiogenic agents, however. For example, 
T4 acts on platelet integrin v3 to cause agglutination [35], 
whereas T3, DITPA and GC-1 do not act on platelets. As a 
pro-angiogenic agent in the context of wound-healing, T4 
would be more desirable than other analogues. In the setting 
of an ischemic organ or tissue, however, a pro- angiogenic 
agent should not promote aggregation of platelets. While T3 
is more potent than T4 as an activator of cellular events that 
involve the intranuclear thyroid hormone receptor (TR1, 
TR1), T4 and T3 are equipotent at the cell surface receptor 
and a case can be made at this receptor for the function of T4 
as a hormone, rather than as a prohormone antecedent of T3 
[36]. 
  Tetraiodothyroacetic acid (tetrac) is a deaminated form of 
T4 (Fig. 1) that is not an agonist at the receptor, but inhibits 
binding of agonist analogues to the integrin [13, 37]. Thus, 
tetrac is a useful probe of the participation of the receptor in 
actions of thyroid hormone analogues. Inside the cell, 
however, tetrac is a low-grade thyromimetic agent [38]. 
Thus, the most stringent application of tetrac as a marker of 
participation of the receptor in the actions of thyroid 
hormones is as re-formulations that cannot gain entry to the 
cell interior. One such re-formulation is nanoparticulate 
(poly[lactate-co-glycolic acid], PLGA) tetrac [39].  
  In addition to transduction of the iodothyronine signal 
vertically to the cell interior from the integrin receptor, the 
hormone-activated receptor on v3 may alter the activities 
of specific polypeptide growth factor receptors that appear to 
be clustered with the integrin on the plasma membrane. For 
example, the epidermal growth factor (EGF)-like ligands 
bind to the cell surface EGF receptor (EGFR) and may have 
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cell surface [34]. EGFR is found in heart cells [40] and 
EGFR signaling may be involved in myocardial hypertrophy 
[41]. In addition, EGFR signaling can result in VEGF and 
bFGF production [42], although this has been described in 
tumor cells and has not yet been looked for in 
myocardiocytes. These observations indicate the complexity 
of regulation of angiogenesis and imply that thyroid 
hormone can influence angiogenesis secondarily via  the 
EGFR and an integrin receptor-EGFR interaction. 
INDUCTION OF ANGIOGENESIS BY THYROID 
HORMONE 
  Several model systems have been exploited to 
demonstrate the pro-angiogenic activity of thyroid hormone. 
As noted above, these initially have been the CAM and the 
HDMEC models and now include a rabbit hind limb 
ischemia model. Translation of studies involving cultured 
cells or the CAM assay into intact animal organ or tissue 
ischemia is a critical step in establishing the utility of the 
pro-angiogenic activity of thyroid hormone analogues. A 
rabbit hind-limb ischemia paradigm has been recently used 
in testing the angiogenic effect of thyroid hormone in an 
intact animal [43]. In these initial intact animal studies, 
increase in angiogenesis has been quantitated by measuring 
blood vessel buds on limb angiography and by the ratio of 
blood vessels to muscle fiber on muscle biopsy.  
  What are the steps that follow activation of MAPK 
(ERK1/2) by thyroid hormone at the cell membrane receptor 
and that lead to neovascularization? The sequence of events 
is incompletely understood, but is known to require 
importation of activated (tyrosine-phosphorylated) ERK1/2 
into the nucleus and its consequence, transcription of the 
basic fibroblast growth factor (bFGF) gene. In the CAM 
assay, the addition of anti-bFGF protein blocks the pro-
angiogenic effect of thyroid hormone [10]. We know that the 
vascular endothelial growth factor (VEGF) gene may also be 
transcribed in response to the binding of thyroid hormone by 
the integrin receptor [44]. Finally, accumulation of Ang-2, 
but not Ang-1, has been shown to occur in endothelial cells 
stimulated by thyroid hormone analogues via the cell surface 
receptor [45]. This is what is expected as a step preparatory 
to the action on endothelium of VEGF [4], in contrast to 
another report cited above in which the hormone enhanced 
tissue accumulation of endothelium stabilizing Ang-1 [3].  
  What transcription factor activities are modulated by 
activated MAPK is not yet known, but thyroid hormone-
directed MAPK is known to activate (phosphorylate) 
members of the nuclear superfamily of hormone receptors, 
such as TR1 and estrogen receptor- (ER) [46, 47]. These 
superfamily members are transcription factors whose 
activation involves phosphorylation and liganding, 
respectively, of T3 or estradiol. T3 has been shown to 
increase expression of the VEGF gene in a model of liver 
regeneration [44, 48] and thyroid hormone administration to 
intact animals, as noted above, can increase bFGF 
expression [1].  
  If TR isoforms are in fact involved in the pro-angiogenic 
action of iodothyronines that begin at the cell surface, then 
this is an example of the interface of membrane-initiated 
actions and downstream effects involving TR in which 
thyroid hormone need not be present in the cell nucleus. 
Nongenomic is a term applied to hormone actions that do not 
primarily require intranuclear complexing of hormone and 
relevant superfamily nuclear receptor family member [37, 
39]. Nongenomic actions may involve the iodothyronine 
receptor on plasma membrane integrin v3, or nuclear TR 
isoforms that are now appreciated to reside in cytoplasm [39, 
49].  
  The signal transduction and activator of transcription 
(STAT) family, such as STAT1 [32], and STAT3 [33], are 
also serine phosphorylated by thyroid hormone-activated 
ERK1/2. These cellular polyfunctional proteins are involved 
in the actions of a variety of cytokines [50], including the 
interferons, as noted above. While the STATs are activated 
primarily by tyrosine phosphorylation [51], specific serine 
phosphorylation of these proteins amplifies their 
transcriptional activity [26, 32]. The STAT proteins are 
involved in vascular growth factor biochemistry. For 
example, the VEGF signal is transduced by STAT1 [52] and 
STAT3 can be involved in VEGF gene expression [53] and 
either or both of these processes, based upon what we know 
about thyroid hormone, may be sites of hormone action that 
contribute to angiogenesis. The FGF receptor (FGFR) on the 
cell surface, when liganded, generates an intracellular signal 
that is STAT1-mediated [54]. Again, iodothyronines could 
amplify transduction of this signal and thus enhance 
angiogenesis. Finally, glycoprotein 130 (gp130) is an 
intracellular signaling protein activated in cardiac myocytes 
in the process of tissue hypertrophy. Via STAT3, gp130 can 
induce  VEGF gene transcription [55] that is required for 
support of hypertrophy. This molecular signaling system is a 
candidate contributor to the studies mentioned above in 
which thyroid hormone induced myocardial hypertrophy [1] 
and one can speculate that amplification of STAT3 action by 
thyroid hormone-directed ERK1/2 might be the vehicle by 
which thyroid hormone can enhance angiogenesis whether or 
not cardiac hypertrophy is present. In summary, the STATs 
are attractive, but as yet unproved, candidate molecular 
mediators of thyroid hormone-induced neovascularization in 
the heart. 
REFORMULATED THYROID HORMONE 
ANALOGUES THAT ACT AT THE INTEGRIN 
RECEPTOR 
 Unmodified  T4 and T3 can act at the cell surface or can be 
taken up by cells via transport systems [56, 57]. Within the 
cell or at the plasma membrane, T4 must be converted to T3 
in order to have nuclear or mitochondrial effects [57-59]. 
However, T4 can affect the state of the cytoskeleton without 
conversion to T3; further, rT3, but not T3, can also effect 
conversion of soluble actin to fibrous (F) actin in the cell 
[60]. Metabolism of T4 or T3 to T2 may be important to 
regulation of oxidative phosphorylation in mitochondria 
[61].  
  Thyroid hormone must be reformulated in order to obtain 
analogues that act exclusively at the integrin. Thyroid 
hormone (T4 or T3) with an agarose tail, although not taken 
up by the cell, stimulates angiogenesis [10]. A thyroid 
hormone nanoparticulate analogue we have developed is T4-
poly (lactate-co-glycolic acid) (PLGA), mentioned above, 
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This agent is pro-angiogenic in the CAM and HDMEC 
microtubular models (Mousa SA, unpublished observations). 
Thus, the outer ring hydroxyl is not critical to the angiogenic 
action of the hormone.  
POSSIBLE APPLICATIONS OF THYROID 
HORMONE ANALOGUES AS PRO-ANGIOGENIC 
AGENTS 
  As indicated above, short-term systemic administration 
of thyroid hormone can induce angiogenesis in an animal 
model of limb ischemia [43]. We have concluded from the 
CAM and HDMEC models of angiogenesis that neovas-
cularization induced by iodothyronines is initiated at the 
integrin receptor for the hormone. Re-formulation of pro-
angiogenic thyroid hormone analogues as agents that act 
exclusively at integrin v3 and that do not enter the cell is 
desirable and has been achieved as iodothyronine nanopar-
ticulates. It is proposed that these re-formulations may be 
administered locally for relief of blood vessel stenosis or 
occlusion by induction of new blood vessels. T3, DITPA and 
GC-1, but not T4, are suitable analogues for this use. Local 
short-term administration may be via temporary stents that 
are coated with thyroid hormone nanoparticles or by catheter 
proximal to stenoses in large vessels. Temporary stents are 
proposed because of the adverse events associated with 
permanent intravascular stents.  
  The anti-angiogenic property of tetrac, a thyroid hormone 
antagonist that acts at the integrin receptor for the hormone 
[13, 45], has been demonstrated in an intact animal model. 
Nude mouse recipients of a human cancer (medullary 
carcinoma of the thyroid gland) have been treated with 
parenteral tetrac or nanoparticulate tetrac for three weeks. 
The experimental cohort demonstrated a 60% decrease in 
tumor-associated vascularity, compared to control animals 
[62].  
CONCLUSIONS 
  Thyroid hormone analogues are now recognized to be 
pro-angiogenic. These analogues include T4, T3, DITPA and 
GC-1. Studied in vitro, the pro-angiogenic activity of these 
analogues appears to be at a cell surface receptor for the 
hormone leading to transduction of the hormone signal by 
MAPK (ERK1/2). The proximate effectors of angiogenesis 
are bFGF and, very likely, VEGF. That is, an effect of the 
hormone initiated at the cell surface and that does not 
necessarily involve access of hormone to the cell interior, 
culminates in gene expression relevant to neovascularization. 
In intact animals, hypothyroidism has been shown to result 
in decreased blood vessel density in brain and heart and this 
is corrected by thyroid hormone administration. In studies of 
a hind limb ischemia model in intact rabbit, thyroid hormone 
administration induces new blood vessel formation. Thus, 
evidence from intact animals suggests that circulating 
thyroid hormone supports angiogenesis. It may be useful to 
test local, short-term administration of thyroid hormone 
analogues, for example, via  temporary thyroid hormone-
coated stents in management of ischemic tissues. T4 should 
not be used for pro-angiogenic intent in vessels because it 
causes platelet agglutination, whereas T3, DITPA and GC-1 
do not have this platelet effect.  
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